Neurosterix is a biopharmaceutical firm dedicated to creating allosteric modulators for the treatment of neurological illnesses.
Neurosterix has raised $63.0M in total funding. The most recent round was Series A. The last funding was announced in April 2024.
Neurosterix's investors include Perceptive Advisors, Xontogeny, Acorn Bioventures.
Neurosterix is headquartered in Geneva, Switzerland.
Neurosterix is a biopharmaceutical firm dedicated to creating allosteric modulators for the treatment of neurological illnesses.
Neurosterix is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neurosterix — Funding & Investors." VCBacked, April 3, 2024, https://www.vcbacked.co/company/neurosterix. Accessed September 14, 2026.
VCBacked. (2024). Neurosterix — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/neurosterix
{{cite web |title=Neurosterix — Funding & Investors |url=https://www.vcbacked.co/company/neurosterix |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated